Use of Angiotensin System Inhibitors is Associated with Immune Activation and Longer Survival in Non-Metastatic Pancreatic Ductal Adenocarcinoma

PURPOSE: Angiotensin system inhibitors (ASIs) can improve prognosis in multiple cancer types, including pancreatic ductal adenocarcinoma (PDAC). However, no study has examined the effect of ASIs alone or combined with adjuvant chemotherapy in resected PDAC patients. EXPERIMENTAL DESIGN: We performed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Liu, Hao, Naxerova, Kamila, Pinter, Matthias, Incio, Joao, Lee, Hang, Shigeta, Kohei, Ho, William, Crain, Jonathan, Jacobson, Alex, Michelakos, Theodoros, Dias-Santos, Daniella, Zanconato, Andrea, Hong, Theodore S, Clark, Jeffrey W, Murphy, Janet E, Ryan, David P, Deshpande, Vikram, Lillemoe, Keith D, Castillo, Carlos Fernandez-del, Downes, Michael, Evans, Ronald M, Michaelson, James, Ferrone, Cristina R, Boucher, Yves, Jain, Rakesh K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856249/
https://ncbi.nlm.nih.gov/pubmed/28600474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0256
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados